Factor S.A. Stewart / Lang A. Anthony / Weiner W.J. William
Drug Induced Movement Disorders
Herausgeber: Factor, Stewart; Weiner, William; Lang, Anthony
Factor S.A. Stewart / Lang A. Anthony / Weiner W.J. William
Drug Induced Movement Disorders
Herausgeber: Factor, Stewart; Weiner, William; Lang, Anthony
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.
Andere Kunden interessierten sich auch für
KaminskyMyasthenia Gravis and Related Disorders171,99 €
Parkinsonian Disorders in Clinical Practice80,99 €
Neurological Investigations115,99 €
Roongroj BhidayasiriNeurological Differential Diagnosis114,99 €
Stroke Units85,99 €
Vascular Dementia239,99 €
Neuromuscular Disorders99,99 €-
-
-
The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.
Produktdetails
- Produktdetails
- Verlag: Wiley
- 2nd Revised edition
- Seitenzahl: 482
- Erscheinungstermin: 11. Februar 2005
- Englisch
- Abmessung: 235mm x 157mm x 30mm
- Gewicht: 845g
- ISBN-13: 9781405126199
- ISBN-10: 1405126191
- Artikelnr.: 22170811
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Wiley
- 2nd Revised edition
- Seitenzahl: 482
- Erscheinungstermin: 11. Februar 2005
- Englisch
- Abmessung: 235mm x 157mm x 30mm
- Gewicht: 845g
- ISBN-13: 9781405126199
- ISBN-10: 1405126191
- Artikelnr.: 22170811
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Dr. Stewart Factor, DO. Professor of Neurology, Riley Family Chair in Parkinson's Disease, Director, Parkinson's Disease and Movement Disorder Program, Albany Medical Center Dr. Anthony E. Lang, MD. Movement Disorder Clinic, Toronto Western Hospital Dr. William J. Weiner, MD. Chair, Department of Neurology, University of Maryland School of Medicine
Section 1: General Considerations.
Chapter 1: Movement Disorders: Approach, Definitions and differential
Diagnosis.
Martin Cloutier, Anthony E. Lang.
Chapter 2: Rating Scales for Movement Disorders.
Wonodi I, Hong EH, Avila MT, Gunvant Thaker.
Chapter 3: Spontaneous movement disorders in psychiatric patients.
Irene Richard, Christopher O'Brien, Roger Kurlan.
Section 2: Antipsychotics.
Chapter 4: Pharmacology of typical and atypical agents.
Gary Remington, Shitij Kapur.
Chapter 5: Acute Drug-induced Dystonia.
Michael F. Mazurek, Patricia I. Rosebush.
Chapter 6: Drug-Induced Parkinsonism.
Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.
Chapter 7: Acute Akathisia.
Author: Lenard A. Adler, John Rotrosen, Burt Angrist.
Chapter 8: Neuroleptic Malignant Syndrome.
Stewart A. Factor.
Chapter 9: Classical Tardive Dyskinesia.
Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.
Chapter 10: Tardive dyskinesia Variants.
Skidmore F, Weiner W, Burke R.
Chapter 11: Movement Disorders caused by atypical antipsychotics.
Karen E. Anderson.
Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.
.
.
Section 3: Dopaminomimetic Drugs.
Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in
Parkinson's disease.
John G. Nutt, Matthew Brodsky.
Chapter 14: Stimulant Drugs.
Anthony E. Munson, Juan Sanchez-Ramos, William J Weiner.
Section 5: Other Drugs.
Chapter 15: Antidepressants.
Marie L. Moro-de-Casillas, David E. Riley.
Chapter 16: Anticonvulsants.
John C. Morgan, Madeline Harrison.
Chapter 17: Miscellaneous Drugs.
Daniel Tarsy
Chapter 1: Movement Disorders: Approach, Definitions and differential
Diagnosis.
Martin Cloutier, Anthony E. Lang.
Chapter 2: Rating Scales for Movement Disorders.
Wonodi I, Hong EH, Avila MT, Gunvant Thaker.
Chapter 3: Spontaneous movement disorders in psychiatric patients.
Irene Richard, Christopher O'Brien, Roger Kurlan.
Section 2: Antipsychotics.
Chapter 4: Pharmacology of typical and atypical agents.
Gary Remington, Shitij Kapur.
Chapter 5: Acute Drug-induced Dystonia.
Michael F. Mazurek, Patricia I. Rosebush.
Chapter 6: Drug-Induced Parkinsonism.
Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.
Chapter 7: Acute Akathisia.
Author: Lenard A. Adler, John Rotrosen, Burt Angrist.
Chapter 8: Neuroleptic Malignant Syndrome.
Stewart A. Factor.
Chapter 9: Classical Tardive Dyskinesia.
Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.
Chapter 10: Tardive dyskinesia Variants.
Skidmore F, Weiner W, Burke R.
Chapter 11: Movement Disorders caused by atypical antipsychotics.
Karen E. Anderson.
Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.
.
.
Section 3: Dopaminomimetic Drugs.
Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in
Parkinson's disease.
John G. Nutt, Matthew Brodsky.
Chapter 14: Stimulant Drugs.
Anthony E. Munson, Juan Sanchez-Ramos, William J Weiner.
Section 5: Other Drugs.
Chapter 15: Antidepressants.
Marie L. Moro-de-Casillas, David E. Riley.
Chapter 16: Anticonvulsants.
John C. Morgan, Madeline Harrison.
Chapter 17: Miscellaneous Drugs.
Daniel Tarsy
Section 1: General Considerations.
Chapter 1: Movement Disorders: Approach, Definitions and differential
Diagnosis.
Martin Cloutier, Anthony E. Lang.
Chapter 2: Rating Scales for Movement Disorders.
Wonodi I, Hong EH, Avila MT, Gunvant Thaker.
Chapter 3: Spontaneous movement disorders in psychiatric patients.
Irene Richard, Christopher O'Brien, Roger Kurlan.
Section 2: Antipsychotics.
Chapter 4: Pharmacology of typical and atypical agents.
Gary Remington, Shitij Kapur.
Chapter 5: Acute Drug-induced Dystonia.
Michael F. Mazurek, Patricia I. Rosebush.
Chapter 6: Drug-Induced Parkinsonism.
Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.
Chapter 7: Acute Akathisia.
Author: Lenard A. Adler, John Rotrosen, Burt Angrist.
Chapter 8: Neuroleptic Malignant Syndrome.
Stewart A. Factor.
Chapter 9: Classical Tardive Dyskinesia.
Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.
Chapter 10: Tardive dyskinesia Variants.
Skidmore F, Weiner W, Burke R.
Chapter 11: Movement Disorders caused by atypical antipsychotics.
Karen E. Anderson.
Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.
.
.
Section 3: Dopaminomimetic Drugs.
Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in
Parkinson's disease.
John G. Nutt, Matthew Brodsky.
Chapter 14: Stimulant Drugs.
Anthony E. Munson, Juan Sanchez-Ramos, William J Weiner.
Section 5: Other Drugs.
Chapter 15: Antidepressants.
Marie L. Moro-de-Casillas, David E. Riley.
Chapter 16: Anticonvulsants.
John C. Morgan, Madeline Harrison.
Chapter 17: Miscellaneous Drugs.
Daniel Tarsy
Chapter 1: Movement Disorders: Approach, Definitions and differential
Diagnosis.
Martin Cloutier, Anthony E. Lang.
Chapter 2: Rating Scales for Movement Disorders.
Wonodi I, Hong EH, Avila MT, Gunvant Thaker.
Chapter 3: Spontaneous movement disorders in psychiatric patients.
Irene Richard, Christopher O'Brien, Roger Kurlan.
Section 2: Antipsychotics.
Chapter 4: Pharmacology of typical and atypical agents.
Gary Remington, Shitij Kapur.
Chapter 5: Acute Drug-induced Dystonia.
Michael F. Mazurek, Patricia I. Rosebush.
Chapter 6: Drug-Induced Parkinsonism.
Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.
Chapter 7: Acute Akathisia.
Author: Lenard A. Adler, John Rotrosen, Burt Angrist.
Chapter 8: Neuroleptic Malignant Syndrome.
Stewart A. Factor.
Chapter 9: Classical Tardive Dyskinesia.
Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.
Chapter 10: Tardive dyskinesia Variants.
Skidmore F, Weiner W, Burke R.
Chapter 11: Movement Disorders caused by atypical antipsychotics.
Karen E. Anderson.
Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.
.
.
Section 3: Dopaminomimetic Drugs.
Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in
Parkinson's disease.
John G. Nutt, Matthew Brodsky.
Chapter 14: Stimulant Drugs.
Anthony E. Munson, Juan Sanchez-Ramos, William J Weiner.
Section 5: Other Drugs.
Chapter 15: Antidepressants.
Marie L. Moro-de-Casillas, David E. Riley.
Chapter 16: Anticonvulsants.
John C. Morgan, Madeline Harrison.
Chapter 17: Miscellaneous Drugs.
Daniel Tarsy







